Novartis Highlights New 96-Week Results From Phase III Scemblix® ASC4FIRST Trial At ASH And Late-Breaking Analysis From ...
(MENAFN- GlobeNewsWire - Nasdaq) Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease- …